- Home
- MDGL vs BBIO Comparison
MDGL vs BBIO Comparison
Compare MDGL & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- BBIO
- Stock Information
- Founded
- MDGL 2011
- BBIO 2015
- Country
- MDGL United States
- BBIO United States
- Employees
- MDGL N/A
- BBIO N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- MDGL Health Care
- BBIO Health Care
- Exchange
- MDGL Nasdaq
- BBIO Nasdaq
- Market Cap
- MDGL 9.6B
- BBIO 9.4B
- IPO Year
- MDGL N/A
- BBIO 2019
- Fundamental
- Price
- MDGL $431.89
- BBIO $54.59
- Analyst Decision
- MDGL Strong Buy
- BBIO Strong Buy
- Analyst Count
- MDGL 12
- BBIO 16
- Target Price
- MDGL $521.09
- BBIO $65.25
- AVG Volume (30 Days)
- MDGL 271.9K
- BBIO 1.9M
- Earning Date
- MDGL 10-28-2025
- BBIO 11-11-2025
- Dividend Yield
- MDGL N/A
- BBIO N/A
- EPS Growth
- MDGL N/A
- BBIO N/A
- EPS
- MDGL N/A
- BBIO N/A
- Revenue
- MDGL $515,547,000.00
- BBIO $235,812,000.00
- Revenue This Year
- MDGL $394.08
- BBIO $115.46
- Revenue Next Year
- MDGL $61.80
- BBIO $65.03
- P/E Ratio
- MDGL N/A
- BBIO N/A
- Revenue Growth
- MDGL 3421.98
- BBIO 7.62
- 52 Week Low
- MDGL $200.63
- BBIO $21.72
- 52 Week High
- MDGL $463.63
- BBIO $57.49
- Technical
- Relative Strength Index (RSI)
- MDGL 50.88
- BBIO 54.25
- Support Level
- MDGL $418.88
- BBIO $53.72
- Resistance Level
- MDGL $451.02
- BBIO $57.48
- Average True Range (ATR)
- MDGL 16.60
- BBIO 1.72
- MACD
- MDGL -2.51
- BBIO -0.08
- Stochastic Oscillator
- MDGL 33.49
- BBIO 48.67
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.